Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BIAF

BioAffinity Technologies Inc

Dec 12 • 04:00PM ET

0.9738

Dollar change +0.0187
Percentage change 1.96	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: CDXS AVDX BNGO CRSP EDIT NTLA SGMO BLUE GILD VRTX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.80	Insider Own	39.38%	Shs Outstand	13.42M	Perf Week	-7.70%
Market Cap	15.17M	Forward P/E	-	EPS next Y	-0.66	Insider Trans	0.00%	Shs Float	9.45M	Perf Month	-23.92%
Income	-8.45M	PEG	-	EPS next Q	-0.14	Inst Own	3.00%	Short Float	1.41%	Perf Quarter	-44.03%
Sales	9.37M	P/S	1.62	EPS this Y	24.18%	Inst Trans	17.05%	Short Ratio	1.05	Perf Half Y	-53.79%
Book/sh	0.23	P/B	4.19	EPS next Y	4.35%	ROA	-100.90%	Short Interest	0.13M	Perf Year	-30.44%
Cash/sh	0.05	P/C	19.96	EPS next 5Y	-	ROE	-167.00%	52W Range	0.92 - 3.62	Perf YTD	-33.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.28%	ROI	-207.99%	52W High	-73.10%	Beta	2.92
Dividend TTM	-	Quick Ratio	1.01	Sales past 5Y	13156.86%	Gross Margin	28.62%	52W Low	5.94%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	1.02	EPS Y/Y TTM	5.64%	Oper. Margin	-89.13%	RSI (14)	29.73	Volatility	9.26% 8.51%
Employees	75	Debt/Eq	0.55	Sales Y/Y TTM	2813.87%	Profit Margin	-90.16%	Recom	1.00	Target Price	6.00
Option/Short	No / Yes	LT Debt/Eq	0.30	EPS Q/Q	38.69%	Payout	-	Rel Volume	0.77	Prev Close	0.96
Sales Surprise	-7.43%	EPS Surprise	-6.67%	Sales Q/Q	687.44%	Earnings	Nov 14 BMO	Avg Volume	127.10K	Price	0.97
SMA20	-15.90%	SMA50	-30.67%	SMA200	-50.07%	Trades		Volume	97,705	Change	1.96%

Today 08:00AM	bioAffinity Technologies Set for Continued Expansion in 2025 (Business Wire)
Dec-05-24 08:00AM	Veterans Research Foundation Spotlights CyPath Lungs Addition to the Federal Supply Schedule (Business Wire)
Nov-14-24 08:00AM	bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 (Business Wire)
Nov-04-24 08:00AM	bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development (Business Wire)
Oct-30-24 08:00AM	bioAffinity Technologies Announces Award of Japanese Patent for CyPath Lung (Business Wire) +5.38%
11:39AM	Loading…
Oct-21-24 11:39AM	WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement (PR Newswire)
10:45AM	bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement (Business Wire)
Oct-18-24 02:57PM	WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement (PR Newswire) -33.80%
12:45PM	bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement (Business Wire)
Oct-16-24 08:00AM	bioAffinitys CyPath Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines (Business Wire) +10.10%
Oct-10-24 08:00AM	bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer (Business Wire)
Oct-09-24 08:00AM	bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath Lung Test (Business Wire) +13.71%
Sep-18-24 08:00AM	Peer-Reviewed Study: bioAffinity Technologies CyPath Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis (Business Wire)
Aug-23-24 05:15PM	bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO (Business Wire)
Aug-14-24 09:25AM	bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath Lung Sales (Business Wire)
02:00PM	Loading…
Aug-05-24 02:00PM	WallachBeth Capital Announces Closing of bioAffinity Technologies Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (PR Newswire)
01:17PM	bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (Business Wire)
Aug-02-24 10:00AM	WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (PR Newswire) -27.31%
09:25AM	bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million (Business Wire)
Jul-12-24 09:35AM	Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jul-09-24 08:00AM	bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath Lung (Business Wire) +7.17%
Jul-05-24 09:00AM	BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-12-24 08:00AM	bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath Lung Tests (Business Wire)
May-15-24 09:55PM	BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q1 2024 (InvestorPlace) +30.32%
09:15AM	bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath Lung Sales and Increased Laboratory Volumes (Business Wire)
May-02-24 08:00AM	bioAffinity Technologies News Update (Business Wire) -6.53%
Apr-24-24 08:00AM	bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth (Business Wire) -5.41%
Apr-09-24 08:00AM	bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening (Business Wire)
Apr-01-24 10:53PM	BIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023 (InvestorPlace)
09:49AM	bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
01:15PM	Loading…
Mar-08-24 01:15PM	Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
12:45PM	bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement (Business Wire)
Mar-06-24 10:45AM	WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire) -50.00%
09:46AM	bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement (Business Wire)
Mar-05-24 08:00AM	bioAffinity Technologies Reports Accelerating Sales Growth of CyPath Lung (Business Wire) +27.66%
Feb-21-24 08:00AM	bioAffinity Technologies News Update (Business Wire)
Feb-06-24 08:00AM	Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies Medical and Scientific Advisory Board and Incorporates CyPath Lung into Medical Practice (Business Wire)
Jan-30-24 08:00AM	bioAffinity Technologies In The News (Business Wire)
Jan-23-24 08:00AM	bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer (Business Wire)
Jan-08-24 08:00AM	bioAffinity Technologies In the News (Business Wire)
Jan-05-24 09:00AM	bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV (ACCESSWIRE)
Dec-05-23 08:00AM	bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors (Business Wire)
Nov-30-23 08:00AM	CMS Posts Final Payment Determination for bioAffinity Technologies CyPath Lung Effective January 2024 (Business Wire) +22.96%
Nov-28-23 08:00AM	bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post (Business Wire)
Nov-15-23 08:00AM	bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening (Business Wire)
Nov-14-23 04:01PM	bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-06-23 08:00AM	bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales (Business Wire)
Oct-10-23 08:00AM	bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference (Business Wire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -31.17%
Sep-19-23 08:00AM	bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services (Business Wire)
Sep-07-23 08:00AM	bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference (Business Wire)
Aug-14-23 05:03PM	bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-12-23 08:00AM	AMA Issues CPT Code for bioAffinity Technologies CyPath® Lung Test for Early-Stage Lung Cancer (Business Wire)
Jun-15-23 08:00AM	bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium (Business Wire)
May-22-23 08:00AM	bioAffinity Technologies Presents Research Findings at CYTO 2023 (Business Wire)
May-15-23 08:00AM	bioAffinity Technologies Reports First Quarter 2023 Financial Results (Business Wire)
May-01-23 08:00AM	bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer (Business Wire) +5.13%
Apr-25-23 08:00AM	bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium (Business Wire)
Apr-05-23 08:00AM	bioAffinity Technologies to Ring Nasdaq Closing Bell Today (Business Wire) +7.78%
Mar-31-23 05:52PM	bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire) +5.00% -13.23%
Mar-28-23 08:00AM	bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer (Business Wire)
Mar-24-23 08:00AM	bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 (Business Wire)
Feb-13-23 08:00AM	bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications (Business Wire)
Jan-24-23 08:00AM	bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research (Business Wire) +75.47%
Jan-04-23 08:00AM	bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments (Business Wire) +5.77%
Dec-19-22 11:33AM	Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) (PR Newswire)
Dec-15-22 08:30AM	bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench (Business Wire)
Dec-01-22 08:00AM	bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting (Business Wire)
Nov-14-22 07:30AM	bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-10-22 08:15AM	bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Companys Scientific and Medical Advisory Board (Business Wire) +7.34%
Nov-08-22 08:00AM	bioAffinity Technologies to Report Third Quarter 2022 Financial Results (Business Wire)
Oct-25-22 09:15AM	bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia (Business Wire)
Oct-12-22 08:15AM	bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference (Business Wire)
Sep-28-22 08:15AM	bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M (Business Wire) +37.74%
Sep-14-22 08:15AM	bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE (Business Wire) +17.39%
Sep-06-22 01:54PM	WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering (PR Newswire) -23.55%
11:28AM	bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering (Business Wire)
Sep-01-22 12:32PM	WallachBeth Capital Announce Pricing Of bioAffinity Technologies IPO At $6.125 Per Unit (PR Newswire)
08:15AM	bioAffinity Technologies Announces Pricing of IPO (Business Wire)

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zannes Maria	President & CEO	Apr 08 '24	Option Exercise	1.16	64,848	75,224	229,506	Apr 24 04:00 PM
Zannes Timothy P	Secretary, EVP, Gen. Counsel	Apr 04 '24	Option Exercise	1.16	64,848	75,224	75,155	Apr 24 04:00 PM
GIRGENTI STEVEN	Director	Apr 03 '24	Option Exercise	1.16	64,848	75,224	1,056,606	Apr 24 04:00 PM
Anderson Robert A.	Director	Feb 26 '24	Option Exercise	1.16	64,848	74,899	121,856	Mar 29 04:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIAF

BioAffinity Technologies Inc

Upgrade your FINVIZ experience